Tweaks to the Affordable Care Act take a back seat
Respondents want federal government to help improve information sharing among organizations
Domestic cat found to harbor resistant IMP-4 gene
Extended-release amantadine treats dyskinesia
Test supports treatment decisions for Tecentriq in NSCLC
National surveys measure APM implementation in commercial, Medicare Advantage, and Medicaid markets
Researchers reconstruct origins of pandemic
OTL 38 attaches to cancer cell receptors
Neutrophil-to-lymphocyte ratio flops in UPenn study

P&T October 2016
Table of Contents


More than a decade of war in the Middle East has pushed post-traumatic stress disorder (PTSD) to the forefront of public health concerns. The author defines the disorder and discusses risk factors, treatments, and the barriers to effective care.
Rising acquisition costs for sodium nitroprusside, indicated for the treatment of perioperative hypertension in cardiac surgery, prompt a medical center to implement a cost-effective alternative that will result in savings of about $300,000 in 2016.
The authors present their findings after conducting a literature review of peer-reviewed articles evaluating the use of dexmedetomidine for the treatment of delirium to support the off-label use of the drug in the intensive care unit.
Meeting Highlights
More than 33,000 cardiologists and allied medical professionals gathered in Rome to share the latest cardiac research. We review key sessions from a wide range of therapeutic areas, including anticoagulation, obesity, and hypercholesterolemia.
Pipeline Plus
Patients with type-2 diabetes can control their blood glucose levels through diet and exercise, by losing excess weight, and by taking medications, such as first-line metformin. We examine several promising drugs in the type-2 diabetes pipeline.


Medication Errors
Risk-reduction strategies for high-alert medication lists
Prescription: Washington
Generic companies press for REMS relief with Senate bill
Approvals, new indications, regulatory activities, and more
Obeticholic acid (Ocaliva) for primary biliary cholangitis; sofosbuvir 400 mg/velpatasvir 100 mg (Epclusa) for chronic hepatitis C virus infection; and daclizumab (Zinbryta) for relapsing multiple sclerosis
Drug Forecast
Mepolizumab (Nucala) for severe eosinophilic asthma


Promising Results for Three Intralesional Oncolytic Agents

Robert H. I. Andtbacka, MD, of the Huntsman Cancer Institute in Utah, reports on three oncolytic immunotherapy studies involving intralesional agents. The combinations of HF10 with ipilimumab and PV-10 with radiation showed promising results, while a study of responders and nonresponders to coxsackievirus A21 suggests avenues for future research.

American Society of Clinical Oncology, June 2016